|
WO2020005935A1
|
|
Glucose uptake inhibitors
|
|
CN111278437A
|
|
RHO-related inhibitors of coiled-coil protein kinase
|
|
CN111050766A
|
|
RHO-related inhibitors of coiled-coil protein kinase
|
|
EP3675861A1
|
|
Inhibitors of rho associated coiled-coil containing protein kinase
|
|
US2020046702A1
|
|
Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors
|
|
CN109310755A
|
|
The bispecific binding protein of PD-L1 and KDR
|
|
WO2017106609A2
|
|
Pdgfr beta antibody
|
|
WO2016210330A1
|
|
Glucose uptake inhibitors
|
|
US2019060314A1
|
|
Treatment of infectious diseases with glucose uptake inhibitors
|
|
WO2016127179A2
|
|
Immunomodulatory agents
|
|
EA036257B1
|
|
Human anti-vegfr-2/kdr antibodies
|
|
WO2015157556A1
|
|
Treatment of gvhd
|
|
CA2942313A1
|
|
Treatment of brain and central nervous system tumors
|
|
US2016340429A1
|
|
Immunomodulatory agents
|
|
US2016237095A1
|
|
Rho kinase inhibitors
|
|
CN105101996A
|
|
Treatment of ocular disorders
|
|
US2015284464A1
|
|
Human anti-VEGFR-2/KDR antibodies
|
|
CA2926478A1
|
|
Rho kinase inhibitors
|
|
WO2013101964A1
|
|
Methods for treatment of breast cancer nonresponsive to trastuzumab
|
|
EP2301528A1
|
|
Use of FTS for treating malignant disorders
|
